Ignite Creation Date:
2024-07-17 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06478381
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-16
Brief Title:
L218CAR19 in Patients With RelapsedRefractory B-cell Lymphoma
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
A Phase 1 Open-label Dose Escalating Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of L218CAR19 in Patients With CD19 Positive RelapsedRefractory B-cell Lymphomas
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells The goal of this study is to determine the safety tolerability pharmacokinetics pharmacodynamics and clinical activity of L218CAR19 in patients with B-cell lymphomas who have received at least two lines of systemic treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None